For the quarter ending 2026-03-31, XENE had $346,704K increase in cash & cash equivalents over the period. -$89,030K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -102,302 | -105,261 | -90,896 | -149,753 |
| Interest receivable and accretion of discounts on marketable securities | 877 | -687 | -177 | -6,505 |
| Depreciation of property plant and equipment | 587 | 611 | 641 | 1,291 |
| Non-cash operating lease expense | 338 | 334 | 330 | 649 |
| Deferred income tax expense (recovery) | 447 | -1,114 | -701 | -1,383 |
| Stock-based compensation expense | 16,894 | 14,115 | 13,705 | 25,887 |
| Unrealized foreign exchange (gain) loss | 204 | -161 | 60 | 28 |
| Unrealized fair value gain on trading securities | - | 0 | - | - |
| Realized (gain) loss on marketable securities | 400 | -18 | -89 | -518 |
| Other receivables | -205 | 559 | -283 | -380 |
| Prepaid expenses and other current assets | 1,482 | -6,628 | 3,373 | 6,412 |
| Accounts payable and accrued liabilities | -1,801 | 3,193 | 5,232 | -2,914 |
| Operating lease liability | -349 | -335 | -337 | -625 |
| Other liabilities | 47 | 41 | 3,158 | - |
| Net cash used in operating activities | -88,897 | -81,481 | -71,752 | -125,885 |
| Purchases of property, plant and equipment | 133 | 318 | 281 | 200 |
| Purchases of marketable securities | 505,652 | 60,900 | 74,702 | 220,055 |
| Proceeds from marketable securities | 98,503 | 123,915 | 113,514 | 337,025 |
| Net cash provided by (used in) investing activities | -407,282 | 62,697 | 38,531 | 116,770 |
| Proceeds from offerings, net | 837,526 | 112,151 | - | - |
| Proceeds from exercise of stock options | 5,487 | 4,962 | - | - |
| Net cash provided by financing activities | 843,013 | 113,537 | 2,360 | 1,216 |
| Effect of exchange rate changes on cash and cash equivalents | -130 | -104 | -6 | 568 |
| Increase (decrease) in cash and cash equivalents | 346,704 | 94,649 | -30,867 | -7,331 |
| Cash and cash equivalents, beginning of period | 199,163 | 104,514 | 142,712 | - |
| Cash and cash equivalents, end of period | 545,867 | 199,163 | 104,514 | - |
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)